Drug Trial Radar · NCT03023111
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
Last checked: Nov 20, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jun 30, 2017
Primary completion
Aug 9, 2019
Study completion Feb 14, 2020
Sponsor
- Lead sponsor
- Hospital Universitário Professor Edgard SantosAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Oswaldo Cruz Foundation
- First posted
- Jan 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cutaneous leishmaniasis (CL) standard treatment is done with parenteral pentavalent antimony (Sbv) at the dose of 15-20mg / kg per day for 20 days. However, therapeutic failure has been described in up to 50% of patients, and the long period of 60 to 90 days required for healing of the ulcerated lesion indicate the need for alternative drugs. Currently the alternatives include other parenteral drugs such as pentamidine and amphotericin B, whose use is limited either by toxicity or because, as with Sbv, the parenteral route hinders adherence and regularity of treatment in the rural area. Recent studies by our group indicate that oral miltefosine is the most effective drug for the treatment of patients with CL caused by L. (V.) guyanensis and L. (V.) braziliensis in Brazil, with a cure rate of 71.4% and 75% respectively. CL pathogenesis is associated with intense inflammatory infiltrate and tissue damage. Previous trials associating GM-CSF to Sbv improved the cure rate of CL caused by L. (V.) braziliensis. The objective of this trial is to evaluate the therapeutic response to the use of miltefosine associated to GM-CSF in the treatment of CL caused by L. (V.) braziliensis in an endemic region in Bahia and Ceará, and by L. (V.) guyanensis in the Amazon region.
Conditions
- Cutaneous Leishmaniasis
Interventions
SbvDrug
Standard treatment for CL, parenteral drug used during 20 days.
Miltefosine plus placeboDrug
Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
Miltefosine plus GM-CSFDrug
Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Final cure rate or complete cicatrization of the ulcerTime frame: 6 months after the end of treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fundação de Medicina Tropical do Amazonas
Manaus, Amazonas, Brazil
Corte de Pedra Health Post
Presidente Tancredo Neves, Estado de Bahia, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.